Skip to main content

Green tea intake and its effect on laboratory parameters and disease symptoms in hospitalised patients with Covid 19: a structured protocol for a randomized controlled trial

Abstract

Objectives

The current randomized controlled trial (RCT) will be conducted to assess the effect of green tea intake on disease symptoms and laboratory parameters including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and complete blood count (CBC) in patients with mild-to-moderate Covid-19 infection.

Trial design

Randomized, double-blinded, parallel (1:1 ratio) clinical trial exploratory study

Participants

We will recruit patients with COVID-19 infection admitted to Yasuj Shahid Jalil Hospital in Yasuj City, Kohgiluyeh and Boyer-Ahmad Province, Iran.

Participants’ inclusion criteria are as follows:

  • Inclusion Criteria

    • Patients aged ≥18 years

    • COVID-19 diagnosis according to real-time polymerase chain reaction (RT-PCR)

  • Exclusion Criteria

    • Pregnancy or lactation

    • Disseminated intravascular coagulation or any other types of coagulopathy

    • Severe congestive kidney failure

    • Having a history of participating in a clinical trial during the last 30 days

Intervention and comparator

Intervention: Two capsules containing 450 mg green tea extract along with routine treatment for COVID-19 patients in the intervention group. Two capsules containing placebo plus routine treatment for patients with COVID-19 infection. Capsules will be taken twice a day, after lunch and dinner, for 14 days.

Main outcomes

Changes in disease symptoms and laboratory parameters including CRP, ESR, and CBC after 14 days of the intervention compared to control group.

Randomisation

Eligible patients will be randomly assigned into the intervention or control group in a 1:1 ratio. Randomization will be performed based on 8 permuted blocks with block sizes of 10, and patients in the intervention and control groups will be matched according to sex and age categories. Randomization will be done using computer-generated random numbers (Randomization.com)

Blinding (masking)

The appearance of placebo and green tea capsules will be similar in terms of shape and color, and they will be packed in the same bags that will be prepared by the company. Also, the researcher and all participants will not be aware of the divisions until the end of the study.

Numbers to be randomised (sample size)

The total sample was determined based on CRP MCID in which high CRP levels were considered >2.6 mg/L. Accordingly, a total sample size of 37 patients for each intervention group was required.

Trial Status

The protocol is Version 1.0, on June 5, 2021. Recruitment will start on July 11, 2021, which is anticipated to be completed by September 21, 2021.

Trial registration

IRCT20150711023153N3 (https://www.irct.ir/trial/55948) retrospectively registered on June 4, 2021

Full protocol

The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting was eliminated; this Letter serves as a summary of the key elements of the full protocol.

Peer Review reports

Availability of data and materials

The final dataset of trial will be available upon request from the primary investigator via e-mail at panahande.b@gmail.com, after obtaining permission from Regional Ethics Committee

Acknowledgements

The authors would like to thank the Yasuj University of Medical Sciences for supporting the present research on COVID-19 and thanks to the Dineh company for contributing to this trial and supplying the green tea supplement and placebo.

Funding

This study was funded and supported by Yasuj University of Medical Sciences, Yasuj, Kohgiluyeh, and Boyer-Ahmad Province, Iran. The funders did not have a role in the design of study, the intervention, collection, analysis, interpretation of data, and writing the manuscript.

Author information

Affiliations

Authors

Contributions

SBP and MY are the Chief Investigators; they conceived the study. SBP, SM, and MY led the proposal and protocol development. MY, AJ, ZH, SM, MRSI, AM and ZS contribute to data collection, SBP, MY, OS study design, and development of proposal. SBP and SM are revising the manuscript. JMM and AP contributed to statistical interpretations. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Seyed Bahman Panahande.

Ethics declarations

Ethics approval and consent to participate

Ethics Committee approved the present trial of Yasuj University of Medical Sciences (Ethics Committee Reference Number: IR.YUMS.REC.1400.027) on May 15, 2021. The investigators declare that the trial has received ethical approval from the appropriate ethics committee, as described above. Informed written consent will be obtained from all participants before randomization.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Full study protocol.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mahmoodi, S., Yousefi, M., Sadeghi, O. et al. Green tea intake and its effect on laboratory parameters and disease symptoms in hospitalised patients with Covid 19: a structured protocol for a randomized controlled trial. Trials 22, 514 (2021). https://doi.org/10.1186/s13063-021-05462-8

Download citation

Keywords

  • COVID-19
  • Randomised controlled trial
  • protocol
  • ESR
  • CRP
  • CBC
  • green tea supplement